Veradermics Doses First Patient in a First-in-Human Clinical Trial for VDPHL for the Treatment of Pattern Hair Loss (Androgenetic Alopecia)
VDPHL is a once-daily non-hormonal oral therapeutic being developed as a treatment for pattern hair loss
New Haven, CONN. (PRWeb) November 7, 2023
Veradermics Inc., a clinical-stage medical dermatology company with a pipeline of first-in-class product candidates targeting highly prevalent immunologic and dermatologic conditions, today announced it has commenced dosing in a First-in-Human clinical trial of VDPHL, an investigational, proprietary, non-hormonal oral treatment being developed for pattern hair loss.
Pattern hair loss, also known as androgenetic alopecia, is the most common form of hair loss in the world, impacting 50 million men and 30 million women in the U.S. alone. Existing treatments include topical minoxidil, which faces high discontinuation rates, and oral finasteride, which is only FDA-approved for men and can be associated with unwanted sexual side effects. Veradermics' VDPHL, a non-hormonal oral therapeutic, has the potential to become a preferred treatment approach for both men and women suffering from pattern hair loss.
"Veradermics is extremely excited to take a step towards addressing the pervasive therapeutic challenge associated with treating pattern hair loss," said Reid Waldman, MD, CEO of Veradermics. "VDPHL is our second proprietary product candidate advanced into clinical trials in 2023, highlighting the company's steadfast commitment in and progress towards developing treatments for common skin conditions."
In 2023, Veradermics also announced the initiation of a Phase 2 trial evaluating VDMN, an immunostimulatory dissolvable microarray patch containing Candida Antigen Extract, for the treatment of common warts. Veradermics' five-asset pipeline also includes product candidates targeting conditions including alopecia areata, atopic dermatitis, and molluscum contagiosum. The company plans to advance multiple additional product candidates into the clinic in 2024.
"The pattern hair loss treatment landscape urgently needs evidence-based solutions," added Tim Durso, MD, President of Veradermics. "An oral, non-hormonal treatment like VDPHL has the potential to dramatically change the way hair loss is treated. We are thrilled to announce the dosing of our first patient and are optimistic about the potential impact of VDPHL in this therapeutic category."
About Veradermics:
Veradermics is a clinical-stage biopharmaceutical company led by experts in dermatology, drug development, and pharmaceutical commercialization that is backed by leading investors in biotech. The company's 5-asset portfolio includes a balance of late-stage and early-stage product candidates targeting highly prevalent immunologic and dermatologic diseases. Founded by dermatologists, Veradermics leverages its front-line clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice. Target indications include common warts, alopecia areata, molluscum contagiosum, androgenetic alopecia (pattern hair loss), and atopic dermatitis. For more information, visit http://www.veradermics.com.
Forward-Looking Statements:
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe", "may" and "will" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of Veradermic's management about VDMN as treatment for patients with skin disease. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. The forward-looking statements are made as of this date and Veradermics does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Media Contact
Reid Waldman, Veradermics
rwaldman@veradermics.com, https://www.veradermics.com/
SOURCE Veradermics Inc.
Veradermics Doses First Patient in Phase 2 Clinical Trial for VDMN for the Treatment of Common Warts
VDMN is an immunotherapy-containing dissolvable microarray being developed as an "injection-free" treatment for common warts
WEST HARTFORD, CONN. (PRWeb) March 24, 2023
Veradermics Inc., a clinical-stage medical dermatology company with a pipeline of first-in-class product candidates targeting highly prevalent skin conditions, today announced that it has commenced enrollment in a Phase 2, 150-person, randomized, double-blind, placebo-controlled clinical trial assessing the safety and efficacy of VDMN in Verruca Vulgaris (common warts).
VDMN is an investigational, proprietary, dissolvable microarray patch technology that administers immunotherapy within the superficial aspect of the skin. It is anticipated that this first-in-category technology will provide an “injection-free” immunotherapy treatment for common warts without creating the degree of pain, “needle-phobia,” and anxiety associated with traditional injections. VDMN has the potential to become a preferred treatment approach for children and young adults where aversion to painful procedures involving needles or freezing with liquid nitrogen and common wart prevalence are all at their highest.
“Common warts, which impact approximately 19 million people in the U.S. alone, are one of the most frequent reasons Americans seek treatment for skin disease,” said Reid Waldman, M.D., CEO at Veradermics. “Despite their high prevalence, there are no FDA approved prescription treatments for common warts. VDMN has the potential to satisfy patient and dermatologist hopes for a convenient, patient-friendly, and effective treatment. The start of our Phase 2 program for VDMN in common warts is a pivotal milestone for Veradermics as the company advances the first product of its pipeline candidates into the clinic.”
VDMN is intended to locally stimulate the immune system resulting in immune system recognition and clearance of the virus that causes common warts – the human papillomavirus (HPV). VDMN is applied immediately adjacent to the wart and left in place for five minutes prior to removal. During this time, the dissolvable microarray releases the immunotherapy-based active ingredient into the epidermis and superficial dermis. In this dose-ranging Phase 2 study, qualified individuals will receive therapy every three weeks for up to six treatments.
"We are very excited to announce the first patient dosed with VDMN, our flagship product candidate,” said Tim Durso, MD, President at Veradermics. “Treatments for common warts are a critical unmet need in dermatology, for which there has been limited advancements for decades. We are optimistic about the potential for VDMN to bring much-needed change to the common wart treatment landscape and look forward to conducting this study.”
About Common Warts:
Common warts are a viral skin infection caused by HPV. Common warts affect ~19 million Americans and result in approximately 2.2 million visits with a healthcare provider annually in the U.S. alone. Common warts may persist for years without treatment. Currently, there are no FDA-approved prescription treatments for this condition.
About Veradermics:
Veradermics Inc. is a medical dermatology company driven to develop innovative therapeutics aimed at transforming the standard of care for a wide range of common skin conditions. Founded by dermatologists, Veradermics leverages its front-line clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice. The company has cultivated a pipeline of diverse, first-in-class therapeutics for highly prevalent dermatologic conditions seen in adults and children. Target indications include common warts, alopecia areata, molluscum contagiosum, androgenetic alopecia (pattern hair loss), and atopic dermatitis. Veradermics is led by an executive team of board-certified dermatologists supported by a board of directors comprised of recognized biopharmaceutical industry leaders. For more information, visit http://www.veradermics.com.
Forward-Looking Statements:
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe", "may" and "will" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of Veradermic’s management about VDMN as treatment for patients with skin disease. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. The forward-looking statements are made as of this date and Veradermics does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Veradermics Contact:
Reid Waldman
Chief Executive Officer
SOURCE Veradermics Inc.